Company Profiles

driven by the PitchBook Platform

Symphogen

Description

Developer of recombinant polyclonal antibodies for the treatment and prevention of infectious diseases and cancer. The company's products include Sym001, a recombinant polyclonal antibody composition for the treatment of idiopathic thrombocytopenic purpura and the prevention of hemolytic disease in newborns; and Sym002, which includes recombinant polyclonal anti-vaccine virus antibodies to treat the adverse reactions caused by smallpox vaccinations.

2000

Founded

PRIVATE

Status

51-200

Employees

Conv. Debt

Latest Deal Type

$75.8M

Latest Deal Amount

$374M

Total Amount Raised

Description

Developer of recombinant polyclonal antibodies for the treatment and prevention of infectious diseases and cancer. The company's products include Sym001, a recombinant polyclonal antibody composition for the treatment of idiopathic thrombocytopenic purpura and the prevention of hemolytic disease in newborns; and Sym002, which includes recombinant polyclonal anti-vaccine virus antibodies to treat the adverse reactions caused by smallpox vaccinations.

Website:

www.symphogen.com

Ownership Status

Privately held (backing)

Financing Status

Venture Capital-Backed

Primary Industry

Drug Discovery

Other Industries

Biotechnology

Primary Office

Pederstrupvej 93 2750 BallerupDenmark +45 4526 5050
Request a free trial to the PitchBook Platform
You're viewing a free company profile from the PitchBook Platform. To explore Symphogen's full profile, request a free trial.

Symphogen Valuation and Funding

Request access
Deal TypeDateAmountRaised to DatePost-ValStatusStage

Symphogen Investors (15)

Request access
Investor NameInvestor TypeHoldingInvestor SinceParticipating RoundsBoard
Seat
Contact
Info
Danica PensionOtherMinority000 0000000 0000
Danske Private EquityPE/BuyoutMinority000 0000000 0000
Essex WoodlandsGrowth/ExpansionMinority000 0000000 0000
GenentechCorporationMinority000 0000000 0000
Gilde Healthcare PartnersVenture CapitalMinority000 0000000 0000
Danica Pension Other
Danske Private Equity PE/Buyout
Essex Woodlands Growth/Expansion
Genentech Corporation
Gilde Healthcare Partners Venture Capital

Symphogen Executive Team (11)

NameTitleBoard
Seat
Contact
Info
Martin OlinChief Executive Officer
Gayle MillsChief Business Officer
Ivan Horak MDChief Scientific & Medical Officer
Michael KraghDirector of Antibody Pharmacology
Jette Wagtberg Şen Ph.DDirector, Antibody Characterization and Analytics
Martin Olin Chief Executive Officer
Gayle Mills Chief Business Officer
Ivan Horak MD Chief Scientific & Medical Officer
Michael Kragh Director of Antibody Pharmacology
Jette Wagtberg Şen Ph.D Director, Antibody Characterization and Analytics

Symphogen Board Members (10)

NameRepresentingRoleSinceContact
Info
Aleks Engel Ph.DNovoBoard Member000 0000
Annika EspanderSelfBoard Member000 0000
Annika JanssonSelfBoard Member000 0000
Anthony Tolcher MDSelfBoard Member000 0000
Göran Ando MDEssex WoodlandsChairman000 0000
Aleks Engel Ph.D Board Member Novo
Annika Espander Board Member Self
Annika Jansson Board Member Self
Anthony Tolcher MD Board Member Self
Göran Ando MD Chairman Essex Woodlands
Request full access to PitchBook